



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

May 17, 2023

Jill Milne
President and Chief Executive Officer
Astria Therapeutics, Inc.
75 State Street, Suite 1400
Boston, Massachusetts 02109

Re: Astria Therapeutics, Inc.
Registration Statement on Form S-3
Filed May 11, 2023
File No. 333-267546

Dear Jill Milne:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Cindy Polynice at 202-551-8707 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Rosemary G. Reilly, Esq.